Damien Vasseur, Ahmadreza Arbab, Fabiola Giudici, Christophe Marzac, Stefan Michiels, Marco Tagliamento, Arnaud Bayle, Cristina Smolenschi, Madona Sakkal, Mihaela Aldea, Hela Sassi, Filippo Gustavo Dall'Olio, Noémie Pata-Merci, Sophie Cotteret, Alice Fiévet, Nathalie Auger, Luc Friboulet, Francesco Facchinetti, Arthur Géraud, Santiago Ponce, Antoine Hollebecque, Benjamin Besse, Jean Baptiste Micol, Antoine Italiano, Ludovic Lacroix, Etienne Rouleau
Next-generation sequencing (NGS) assays based on plasma cell-free DNA (cfDNA) are increasingly used for clinical trials inclusion. Their optimized limit of detection applied to a large number of genes leads to the identification of mutations not confirmed in tissue. It becomes essential to describe the characteristics and consequences of these liquid biopsy-only mutations. In the STING protocol (Gustave Roussy, NCT04932525), 542 patients with advanced solid cancer had cfDNA-based and tissue-based NGS analysis (performed by FoundationOne® Liquid CDx and FoundationOne CDx™, respectively)...
February 26, 2024: NPJ Precision Oncology